Preparation of aspirin and probucol in combination loaded chitosan nanoparticles and in vitro release study

被引:142
作者
Wan Ajun [1 ]
Sun Yan [1 ]
Gao Li [2 ]
Li Huili [3 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Chem & Chem Technol, Shanghai 200240, Peoples R China
[2] Ningxia Univ, Sch Resource & Environm, Yinchuan 750021, Peoples R China
[3] Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200240, Peoples R China
基金
中国国家自然科学基金;
关键词
Aspirin; Probucol; Chitosan nanoparticles; Combination load; In vitro release; TRANSLUMINAL CORONARY ANGIOPLASTY; BALLOON ANGIOPLASTY; DRUG-DELIVERY; GEL BEADS; RESTENOSIS; TYRPHOSTIN; CELLS; POLYMORPHS; POLYMER; COMPLEX;
D O I
10.1016/j.carbpol.2008.08.019
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
We design and develop chitosan nanoparticles which load two different drugs simultaneously. Aspirin (acetylsalicylic acid, ASA), a hydrophilic drug and probucol (PRO), a hydrophobic drug, are chosen as typical drugs, which are widely used to treat restenosis. The drug loaded chitosan nanoparticles are prepared by gelation of chitosan with tripolyphosphate (TPP) by ionic cross-linking. The physicochemical properties of nanoparticles are investigated by FTIR, transmission electron microscope (TEM), scanning electron microscopy (SEM) and differential scanning calorimetry (DSC). The images show that these particles are spherical in shape with ASA being in the amorphous phase, while PRO is crystalline. The properties of chitosan nanoparticles such as encapsulation capacity and controlled release behaviors of ASA and PRO are evaluated. Experimental results indicate that the loading capacity (LC), encapsulation efficiency (EE) and ASA and PRO release behaviors are affected by several factors including pH, concentration of TPP, chitosan molecular weight (MW) and ASA initial concentration as well as PRO. In vitro release shows that the nanoparticles provide a continuous release. Entrapped ASA is released for more than 24 h and PRO lasts longer for 120 h. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:566 / 574
页数:9
相关论文
共 42 条
[1]  
BAIM DS, 1992, HEART DIS TXB CARDIO, P1365
[2]   Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries [J].
Banai, S ;
Chorny, M ;
Gertz, SD ;
Fishbein, I ;
Gao, JC ;
Perez, L ;
Lazarovichi, G ;
Gazit, A ;
Levitzki, A ;
Golomb, G .
BIOMATERIALS, 2005, 26 (04) :451-461
[3]   PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine [J].
Banai, S ;
Wolf, Y ;
Golomb, G ;
Pearle, A ;
Waltenberger, J ;
Fishbein, I ;
Schneider, A ;
Gazit, A ;
Perez, L ;
Huber, R ;
Lazarovichi, G ;
Rabinovich, L ;
Levitzki, A ;
Gertz, SD .
CIRCULATION, 1998, 97 (19) :1960-1969
[4]   A comparison of alternative polymer excipients and processing methods for making solid dispersions of a poorly water soluble drug [J].
Broman, E ;
Khoo, C ;
Taylor, LS .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 222 (01) :139-151
[5]  
Calvo P, 1997, J APPL POLYM SCI, V63, P125, DOI 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO
[6]  
2-4
[7]   RESTENOSIS AFTER PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY - HAVE WE BEEN AIMING AT THE WRONG TARGET [J].
CURRIER, JW ;
FAXON, DP .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 25 (02) :516-520
[8]  
FANG SQ, 1999, CHINESE NEW DRUGS J, V8, P1999
[9]   Nanoparticulate delivery system of a tyrphostin for the treatment of restenosis [J].
Fishbein, I ;
Chorny, M ;
Rabinovich, L ;
Banai, S ;
Gati, I ;
Golomb, G .
JOURNAL OF CONTROLLED RELEASE, 2000, 65 (1-2) :221-229
[10]   Formulation and delivery mode affect disposition and activity of tyrphostin-loaded nanoparticles in the rat carotid model [J].
Fishbein, I ;
Chorny, M ;
Banai, S ;
Levitzki, A ;
Danenberg, HD ;
Gao, JC ;
Chen, X ;
Moerman, E ;
Gati, I ;
Goldwasser, V ;
Golomb, G .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (09) :1434-1439